Andrew Pettitt

Prof. Andrew Pettitt

orcid

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 May 2012 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
APAndrew Pettitt
Andrew Pettitt
RJRichard Jackson
Richard Jackson
SCStacey Carruthers
Stacey Carruthers
JDJames Dodd
James Dodd
SDSusanna Dodd
Susanna Dodd
PHPeter Hillmen
Peter Hillmen
Purpose: In chronic lymphocytic leukemia (CLL), TP53 deletion/mutation is strongly associated with an adverse outcome and resistance to chemotherapy-based treatment. In contrast, TP53 defects are not associated with resistance to the anti-CD52 monoclonal antibody alemtuzumab or methylprednisolone. In an attempt to improve the treatment of TP53-defective CLL, a multicenter phase II study was developed to evaluate alemtuzumab and methylprednisolone in combination. Patients and Methods: Thirty-nine patients with TP53-deleted CLL (17 untreated and 22 previously treated) received up to 16 weeks of treatment with alemtuzumab 30 mg three times a week and methylprednisolone 1.0 g/m2 for five consecutive days every 4 weeks. Antimicrobial prophylaxis consisted of cotrimoxazole, itraconazole, and aciclovir (or valganciclovir for asymptomatic cytomegalovirus viremia). The primary end point was response as assigned by an end-point review committee. Secondary end points were safety, progression-free survival (PFS) and overall survival (OS). Results: The overall response rate, complete response rate (including with incomplete marrow recovery), median PFS, and median OS were 85%, 36%, 11.8 months, and 23.5 months, respectively, in the entire cohort and 88%, 65%, 18.3 months, and 38.9 months, respectively, in previously untreated patients. Grade 3 to 4 hematologic and glucocorticoid-associated toxicity occurred in 67% and 23% of patients, respectively. Grade 3 to 4 infection occurred in 51% of the overall cohort and in 29% of patients less than 60 years of age. Treatment-related mortality was 5%. Conclusion: Alemtuzumab plus methypredisolone is the most effective induction regimen hitherto reported in TP53-deleted CLL. The risk of infection is age related and, in younger patients, seems only marginally higher than that associated with rituximab, fludarabine, and cyclophosphamide.

4 November 2022 in Nature Genetics
Verified
Journal Article
Open access
PDF file
PRPauline Robbe
Pauline Robbe
KRKate E. Ridout
Kate E. Ridout
DVDimitrios V. Vavoulis
Dimitrios V. Vavoulis
HDHelene Dréau
Helene Dréau
BKBen Kinnersley
Ben Kinnersley
ASAnna Schuh
Anna Schuh
The value of genome-wide over targeted driver analyses for predicting clinical outcomes of cancer patients is debated. Here, we report the whole-genome sequencing of 485 chronic lymphocytic leukemia patients enrolled in clinical trials as part of the United Kingdom’s 100,000 Genomes Project. We identify an extended catalog of recurrent coding and noncoding genetic mutations that represents a source for future studies and provide the most complete high-resolution map of structural variants, copy number changes and global genome features including telomere length, mutational signatures and genomic complexity. We demonstrate the relationship of these features with clinical outcome and show that integration of 186 distinct recurrent genomic alterations defines five genomic subgroups that associate with response to therapy, refining conventional outcome prediction. While requiring independent validation, our findings highlight the potential of whole-genome sequencing to inform future risk stratification in chronic lymphocytic leukemia.

15 June 2009 in Cancer Research
Verified
Journal Article
Open access
PDF file
GJGillian G. Johnson
Gillian G. Johnson
PSPaul D. Sherrington
Paul D. Sherrington
ACAnthony Carter
Anthony Carter
KLKe Lin
Ke Lin
TLTriantafillos Liloglou
Triantafillos Liloglou
APAndrew Pettitt
Andrew Pettitt
The ATM-p53 pathway plays an important role in the biology of chronic lymphocytic leukemia (CLL). Its functional integrity can be probed by exposing CLL cells to ionizing radiation (IR) and measuring levels of p53 protein and one of its transcriptional targets, the cyclin-dependent kinase inhibitor p21. We have previously identified two abnormal p53/p21 response patterns associated with inactivating mutations of TP53 and ATM, respectively. Here, we describe a third abnormal response pattern characterized by failure of p21 protein accumulation despite a normal p53 protein response. This so-called "type C" response was detected in 10.6% of unselected patients and was associated with resistance of CLL cells to p53-dependent killing by IR, with the clinically more aggressive variant of CLL characterized by unmutated immunoglobulin heavy-chain genes and with a single nucleotide polymorphism at codon 31 of the p21 gene in which Ser is replaced by Arg. CLL samples with this allelic variant displayed impaired IR-induced up-regulation of total p21 mRNA and did not express the Arg-encoding transcript, except in those cases harboring an additional single nucleotide polymorphism (T instead of C) in the 3′-untranslated region of the same p21 allele. Our data provide new insight into the importance of p21 in CLL biology. [Cancer Res 2009;69(12):5210–17]

19 December 2013 in Blood
Verified
Journal Article
Open access
PDF file
GJGillian G. Johnson
Gillian G. Johnson
KLKe Lin
Ke Lin
TCTrevor F. Cox
Trevor F. Cox
MOMelanie Oates
Melanie Oates
DSDavid R. Sibson
David R. Sibson
APAndrew Pettitt
Andrew Pettitt
Fludarabine plus cyclophosphamide (FC) is the chemotherapy backbone of modern chronic lymphocytic leukemia (CLL) treatment. CYP2B6 is a polymorphic cytochrome P450 isoform that converts cyclophosphamide to its active form. This study investigated the possible impact of genetic variation in CYP2B6 on response to FC chemotherapy in CLL. Available DNA samples from the LRF CLL4 trial, which compared chlorambucil, fludarabine, and FC, were screened by TaqMan real-time polymerase chain reaction assays for CYP2B6 SNPs c.516G>T and c.785A>G, which define the most common variant allele (*6). Among the 455 samples successfully genotyped, 265 (58.2%), 134 (29.5%), and 29 (6.4%) were classified as *1/*1, *1/*6, and *6/*6, respectively. Patients expressing at least one *6 allele were significantly less likely to achieve a complete response (CR) after FC (odds ratio 0.27; P = .004) but not chlorambucil or fludarabine. Analysis of individual response indicators confirmed that this inferior response resulted from impaired cytoreduction rather than delayed hemopoietic recovery. Multivariate analysis controlling for age, gender, stage, IGHV mutational status, 11q deletion, and TP53 deletion/mutation identified CYP2B6*6 and TP53 mutation/deletion as the only independent determinants of CR attainment after FC. Our study provides the first demonstration that host pharmacogenetics can influence therapeutic response in CLL. This trial is registered as an International Standard Randomised Control Trial, number NCT 58585610 at www.clinicaltrials.gov.

19 August 2019 in Leukemia
Verified
Journal Article
Open access
PDF file
KKKarl-Anton Kreuzer
Karl-Anton Kreuzer
RFRichard R. Furman
Richard R. Furman
SSStephan Stilgenbauer
Stephan Stilgenbauer
RDRonald L. Dubowy
Ronald L. Dubowy
YKYeonhee Kim
Yeonhee Kim
MHMichael Hallek
Michael Hallek

9 October 2025 in British Journal of Haematology
Verified
Journal Article
Closed access
RWR. Walewska
R. Walewska
TEToby Eyre
Toby Eyre
ABA. Bloor
A. Bloor
GFG. Follows
G. Follows
SIS. Iyengar
S. Iyengar
PPPiers Patten
Piers Patten